METHOD FOR IDENTIFYING CRITERIA FOR ADEQUATE immunotherapy septic diseases

摘要

way choice of criteria u0434u043bu00a0 u043fu0440u043eu0432u0435u0434u0435u043du0438u00a0 adequate u0438u043cu043cu0443u043du043eu0442u0435u0440u0430u043fu0438u0438 in pyo inflammatory u0437u0430u0431u043eu043bu0435u0432u0430u043du0438u00a0u0445 by assessing immune status before and after u043fu0440u0438u043cu0435u043du0435u043du0438u00a0 u0438u043cu043c u0443u043du043eu043cu043eu0434u0443u043bu00a0u0442u043eu0440u0430 amid u043eu0431u0449u0435u043fu0440u0438u043du00a0u0442u043eu0433u043e u043bu0435u0447u0435u043du0438u00a0, u043eu0442u043bu0438u0447u0430u044eu0449u0438u0439u0441u00a0, u043fu0440u043eu0432u043eu0434u00a0u0442 evaluation of clinical effectiveness of u043bu0435u0447u0435u043du0438u00a0 patients in the group with increased in group with the decrease of immunological u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0 amid u0438u043cu043cu0443u043du043eu0442u0435u0440u0430u043fu0438u0438,if u043du0430u0438u043bu0443u0447u0448u0430u00a0 u043au043bu0438u043du0438u0447u0435u0441u043au0430u00a0 efficiency achieved in the group with higher baseline immunological u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0, u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 possible maximum value and u043cu043cu0443u043du043eu043bu043eu0433u0438u0447u0435u0441u043au043eu0433u043e u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0 group prior to the u0438u043cu043cu0443u043du043eu0442u0435u0440u0430u043fu0438u0438,in the presence of immunological u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0 patient below the maximum u0437u043du0430u0447u0435u043du0438u00a0 this u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0 group the immune boosting u043cu043eu0434u0443u043bu00a0u0442u043eu0440u0430 consider most appropriate, if u043du0430u0438u043bu0443u0447u0448u0430u00a0 u043au043bu0438u043du0438u0447u0435u0441u043au0430u00a0 efficiency achieved in the group with lower baseline immunological u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0,u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 possible minimum value of immunological u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0 group prior to the u0438u043cu043cu0443u043du043eu0442u0435u0440u0430u043fu0438u0438, find the original immunological u043fu043eu043au0430u0437u0430u0442u0435u043b u00a0 patient is above the maximum u0437u043du0430u0447u0435u043du0438u00a0 this u043fu043eu043au0430u0437u0430u0442u0435u043bu00a0 group in the u0438u043cu043cu0443u043du043eu043cu043eu0434u0443u043bu00a0u0442u043eu0440u0430 consider to be the most efficient.